field, but even today there is confusion. The European Academy of Allergy and Clinical Immunology (EAACI) published a new allergy nomenclature in 2001. In this nomenclature, "atopic eczema/dermatitis syndrome" (AEDS) was proposed as an overarching term to replace both AD and AE (Johansson et al., 2001) . The nomenclature was then reviewed by the World Allergy Organization (WAO) in 2004, when "eczema" replaced AEDS, with AE reserved for cases with evidence of allergic sensitization to environmental allergens (Johansson et al., 2004; Figure 2) . However, this suggested change has not been adopted uniformly. It ruffled feathers in particular in countries where eczema is a more general term for skin rashes, and the dermatology community has consequently continued to use AD, AE, and eczema interchangeably.
That alone would not be a disaster because the name by which we call the beast is less important than the comparability of diagnostic criteria and study outcome measures. Brenninkmeijer et al. (2008) recently published a systematic review of the current diagnostic criteria for AD, highlighting the urgent need for consensus. Following publication of the landmark diagnostic criteria presented by Hanifin and Rajka in 1980, which to date remain the most commonly used There has been a significant increase in the prevalence of atopic dermatitis (AD) recently, with about 15-20% of children in developed countries currently affected by the disease (Odhiambo et al., 2009) . AD also affects between 2 and 15% of adults in industrialized countries (Herd et al., 1996; Vartiainen et al., 2002) . The financial burden on patients, their families, and the health-care system and quality of life impairment are significant (McKenna et al., 2007) ; taken together, this has contributed to a heightened interest in AD-related research. Not surprisingly, therefore, the AD literature has grown considerably ( Figure 1 ). This must be welcomed, but often quantity does not translate directly into quality, and, what is more, direct comparability among studies (for instance as part of meta-analyses and quality assessment) is only possible if universal validated diagnostic criteria and outcome tools are used. Unfortunately, the dermatology community has been speaking in many tongues when it comes to AD.
the mess we are in
Terms like "prurigo diasthésique" and "mycosis flexurarum" are (thankfully) echoes of a bygone era, and decades ago AD and atopic eczema (AE) became the most commonly used terms in the The past 2 decades have seen a heightened interest in atopic dermatitis-related research, leading to an exponential increase in publications. However, large numbers of diagnostic criteria and outcome measures hamper study comparability. The Harmonizing Outcome Measures for Eczema (HOME) initiative addresses the urgent need for consensus, but more work will be required. Dermatology (2011 Dermatology ( ) 131, 557-559. doi:10.1038 Dermatology ( /jid.2010 diagnostic criteria for AD, an additional eight criteria have been published. It is important to remember that the Hanifin and Rajka criteria were based on expert consensus, and only the UK refinement of those criteria has been validated in both hospital and community settings (Brenninkmeijer et al., 2008) . They are also the only diagnostic criteria to have been independently validated. Valid diagnostic criteria suitable for hospital studies as well as large population-based surveys should be part of the foundation on which we build epidemiological, laboratory, and clinical trial research. Valid, reliable, and relevant outcome measures must form the other part of this foundation, and we as dermatology researchers have the responsibility to ensure they are put in place.
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How do we get out of the mess?
A systematic review of AD severity measurement tools found that 91% of AD clinical trials used an objective severity measure but that only one-third of these scales had been published (Charman et al., 2003) . Schmitt et al. (2007) consequently assessed the validity and reliability of the 20 most common severity measures for AD, and only 3 performed adequately. This then triggered an international Delphi exercise on outcome measures for AD-Harmonizing Outcome Measures for Eczema (HOME), published by Schmitt et al. (2011, this issue) in an attempt to ensure investigators employ a core set of outcome measures. Modeled on the OMERACT initiative for joint diseases (Tugwell et al., 2007) , the HOME panel consisted not only of clinical experts but also of consumers, editors of US and European dermatology journals, and a regulatory agency representative. Consensus was achieved for universal inclusion of AD symptoms, physician-assessed clinical signs, and a measure of long-term control of flares as core outcome measures. Interestingly, and in contrast to all other stakeholders, the majority of consumers did not think that impact on quality of life needed to be assessed in all AD clinical trials. Of course, this consensus represents only the minimum set of outcome measures; others, depending on the circumstances, can be added by investigators as they see fit. It is important to emphasize that none of the panel members had a vested interest in a specific outcome measure or significant links to the pharmaceutical industry. HOME is a welcome and timely initiative, but it is only the first step in the right direction. Future HOME Delphi rounds will need to address a much more delicate task: developing agreement on the tools used to assess the three identified core outcome domains. Even then, much more remains to be done, such as seeking agreement on diagnostic criteria. Only then will we as dermatologists be wise, rather than foolish builders of our own research foundations, for the benefit of evidence-based dermatology and our patients.
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REfEREnCES
Brenninkmeijer EE, Schram ME, Leeflang MM et al. nonmelanoma skin cancers are among the most common human malignancies. Although typically not lethal, they are responsible for tissue deformity and substantial morbidity, particularly in high-risk populations. Solar UVB radiationa major etiologic factor for this kind of malignancy-produces DnA lesions such as cyclobutane pyrimidine dimers and 6-4 photoproducts in skin. These lesions are removed through nucleotide excision repair because humans lack a DnA glycosylase required to initiate base excision repair of pyrimidine-pyrimidine photoproducts but produce all the other proteins required for this process. In this issue, Johnson et al. show that a DnA glycosylase derived from Chlorella virus and engineered to enhance tissue penetration and nuclear localization can remove UVB-induced DnA lesions in a human skin equivalent model and that the protein can be incorporated into a topical formulation for the prevention and treatment of UVB-induced DnA damage. These results suggest that such an enzyme may be incorporated into regimens for the chemoprevention of skin cancers. (2011) 131, 559-561. doi:10.1038/jid.2010 When UVR interacts with skin, it produces photochemical changes in DNA that can adversely affect the skin's bio logical activities and produce disease. Two lesions most commonly result from UVR exposure: cyclobutane pyrimidine dimers (CPDs), in which adjacent pyrimidine rings are coupled through carbon-carbon double bonds at the 5 and 6 positions, and 6,4-pyrimidine pyrimidone photoproducts, in which adjacent pyrimidines are connected through a single bond between the 6 position of one molecule and the 4 position of the other. These alterations, if not restored to their original state, produce mutations that can ultimately lead to non melanoma skin cancers (NMSCs), including both squamous cell (SCCs) and basal cell carcinomas (BCCs) (Cleaver and Crowley, 2002) . Fortunately, virtually all living organisms possess intricate repair mechanisms to mend damaged DNA. Bulky lesions such as CPDs are normally repaired by nucleotide excision repair, but they can also be restored by base excision repair (BER). Humans, however, can repair CPDs only through nucleotide excision repair (NER). Although human cells have most of the enzymes necessary to complete BER, they lack an important DNA glycosylase required to initiate the process (Cafardi and Elmets, 2008) . The importance of DNA repair for protection from UV-induced skin cancers is evident if one examines individuals who suffer from xeroderma pigmentosum (XP), an inherited disease in which the NER pathway of DNA is deficient. These patients have a propensity to develop extensive photodamage, cutaneous SCCs, BCCs, and melanomas at an unusually early age.
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Even in healthy individuals NMSCs are particularly common. In the United States alone, the estimated 1.5-3.5 million new NMSC diagnoses each year exceed those of all other types of cancer combined. Although rarely lethal, these lesions are locally destructive and the cost of their removal represents an economic burden to the healthcare system. The direct cost for treatment of NMSCs in the United States was estimated to be $1.5 billion in 2004, and if actinic keratoses-premalignant lesions that may progress to SCCs-were included, the direct cost would increase to over $2.3 billion (Bickers et al., 2006) . In contrast to most other malignancies, in which the incidence has stabilized or declined, the rate of NMSCs continues to rise (Athas et al., 2003; Karagas et al., 1999) . Moreover, in a population-based retrospective study from 1976 to 2003, the incidence of BCCs and SCCs in patients under 40 years old was found to be increasing significantly (Christenson et al., 2005) .
Efforts to prevent actinic keratoses and NMSCs have been directed at counseling patients to limit the amount of UVR that reaches the skin, either through avoidance of sun exposure and tanning bed use or through the application of sunscreens. The American Academy of Dermatology, the American Cancer Society, and other organizations throughout the world have developed sophisticated educational
